Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).

被引：32
|
作者：
Usmani, Saad Zafar
Mateos, Maria-Victoria
Nahi, Hareth
Krishnan, Amrita Y.
van de Donk, Niels W. C. J.
San Miguel, Jesus
Oriol, Albert
Rosinol, Laura
Chari, Ajai
Adams, Homer
Girgis, Suzette
Lin, Shun Xin Wang
Stephenson, Tara
Kemmerer, Kristy
Smit, Jennifer
Elsayed, Yusri A.
Infante, Jeffrey R.
Goldberg, Jenna D.
Banerjee, Arnob
Garfall, Alfred L.
机构：
[1] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[2] Univ Hosp Salamanca IBSAL, Salamanca, Spain
[3] Karolinska Inst, Stockholm, Sweden
[4] Karolinska Univ Hosp Huddinge, Stockholm, Sweden
[5] City Hope Natl Med Ctr, Duarte, CA USA
[6] Vrije Univ Amsterdam Med Ctr, Amsterdam Univ, Med Ctr, Amsterdam, Netherlands
[7] Clin Univ Navarra, Pamplona, Spain
[8] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain
[9] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Badalona, Spain
[10] Hosp Clin Barcelona, Barcelona, Spain
[11] Mt Sinai Sch Med, Dept Hematol Oncol, New York, NY USA
[12] Janssen Res & Dev LLC, Spring House, PA USA
[13] Janssen Res & Dev LLC, Raritan, NJ USA
[14] Perelman Sch Med, Philadelphia, PA USA
[15] Abramson Canc Ctr, Philadelphia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
10.1200/JCO.2020.38.15_suppl.100
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
100
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1.
    Martin, Thomas G.
    Moreau, Philippe
    Usmani, Saad Zafar
    Garfall, Alfred L.
    Mateos, Maria-Victoria
    San-Miguel, Jesus F.
    Rocafiguera, Albert Oriol
    Nooka, Ajay K.
    Rosinol, Laura
    Chari, Ajai
    Karlin, Lionel
    Krishnan, Amrita Y.
    Bahlis, Nizar J.
    Popat, Rakesh
    Besemer, Britta
    Martinez, Joaquin
    Delforge, Michel
    Fastenau, John
    Gries, Katharine S.
    van de Donk, Niels W. C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [22] A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen x CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
    D'Souza, Anita
    Shah, Nina
    Rodriguez, Cesar
    Voorhees, Peter M.
    Weisel, Katja
    Bueno, Orlando F.
    Pothacamury, Rajvineeth K.
    Freise, Kevin J.
    Yue, Susan
    Ross, Jeremy A.
    Polepally, Akshanth R.
    Talati, Chetasi
    Lee, Shane
    Jin, Ziyi
    Buelow, Ben
    Vij, Ravi
    Kumar, Shaji
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (31) : 3576 - +
  • [23] Initial Results of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refractory Multiple Myeloma
    Rodriguez, Cesar
    D'Souza, Anita
    Shah, Nina
    Voorhees, Peter M.
    Ben Buelow
    Vij, Ravi
    Kumar, Shaji K.
    BLOOD, 2020, 136
  • [24] POPULATION PHARM ACOKINETICS (POPPK) OF ABBV-383, A B-CELL MATURATION ANTIGEN (BCMA) x CD3 BISPECIFIC T-CELL-REDIRECTING ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Polepally, A.
    Badillo, J.
    Rinas, M.
    Ahsan, A.
    Bueno, O.
    Talati, C.
    Menon, R.
    Engelhardt, B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S69 - S69
  • [25] Correlative biomarker analyses for optimal therapeutic dose determination of ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
    Ahsan, Aarif
    Mantis, Christine
    Luo, Xizhi
    Zhang, Catherine C.
    Valdes, Cesar Rodriguez
    Voorhees, Peter M.
    D'Souza, Anita
    Chung, Alfred
    Tuchman, Sascha
    Safah, Hana
    Mckay, John T.
    Weisel, Katja C.
    Teipel, Raphael
    Korde, Neha
    Vij, Ravi
    Kumar, Shaji
    Bueno, Orlando Felix
    Pothacamury, Rajvineeth Kumar
    Talati, Chetasi
    Ross, Jeremy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM)
    Levy, Moshe
    Bahlis, Nizar
    Raje, Noopur
    Costello, Caitlin
    Dholaria, Bhagirathbhai
    Solh, Melhem
    Tomasson, Michael
    Dube, Harman
    Damore, Michael
    Lon, Hoi Kei
    Basu, Cynthia
    Skoura, Athanasia
    Chan, Edward
    Trudel, Suzanne
    Jakubowiak, Andrzej
    Chu, Michael
    Gasparetto, Cristina
    Dalovisio, Andrew
    Sebag, Michael
    Lesokhin, Alexander
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S439 - S439
  • [27] Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, for Patients With Relapsed/ Refractory Multiple Myeloma (RRMM): Extended Follow-Up and Biweekly Administration From the MagnetisMM-3 Study
    Mohty, Mohamad
    Tomasson, Michael H.
    Arnulf, Bertrand
    Bahlis, Nizar J.
    Prince, H. Miles
    Niesvizky, Ruben
    Rodriguez-Otero, Paula
    Martinez-Lopez, Joaquin
    Koehne, Guenther
    Jethava, Yogesh
    Gabayan, Afshin E.
    Stevens, Don A.
    Nooka, Ajay K.
    Raje, Noopur
    Iida, Shinsuke
    Leip, Eric
    Conte, Umberto
    Czibere, Akos
    Viqueira, Andrea
    Lesokhin, Alexander M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S493 - S494
  • [28] Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): extended follow up and biweekly administration from the MagnetisMM-3 study
    Raab, M. S.
    Haenel, M.
    Mohty, M.
    Tomasson, M. H.
    Arnulf, B.
    Bahlis, N. J.
    Prince, H. M.
    Niesvizky, R.
    Rodriguez-Otero, P.
    Martinez-Lopez, J.
    Koehne, G.
    Jethava, Y.
    Gabayan, A. E.
    Stevens, D. A.
    Nooka, A. K.
    Raje, N.
    Iida, S.
    Leip, E.
    Conte, U.
    Czibere, A.
    Viqueira, A.
    Lesokhin, A. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 177 - 178
  • [29] Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.
    Mohty, Mohamad
    Tomasson, Michael H.
    Arnulf, Bertrand
    Bahlis, Nizar J.
    Prince, H. Miles
    Niesvizky, Ruben
    Rodriguez-Otero, Paula
    Martinez-Lopez, Joaquin
    Koehne, Guenther
    Jethava, Yogesh
    Gabayan, A. Eli
    Stevens, Don A.
    Nooka, Ajay K.
    Raje, Noopur S.
    Iida, Shinsuke
    Leip, Eric
    Conte, Umberto
    Czibere, Akos Gabor
    Viqueira, Andrea
    Lesokhin, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Lesokhin, Alexander M.
    Levy, Moshe Y.
    Dalovisio, Andrew P.
    Bahlis, Nizar J.
    Solh, Melhem
    Sebag, Michael
    Jakubowiak, Andrzej
    Jethava, Yogesh S.
    Costello, Caitlin L.
    Chu, Michael P.
    Savona, Michael R.
    Gasparetto, Cristina
    Trudel, Suzanne
    Chou, Jeffrey
    Udata, Chandrasekhar
    Basu, Cynthia
    Krupka, Heike I.
    Raje, Noopur S.
    BLOOD, 2020, 136
12345